Low levels of tissue inhibitors of metalloproteinases with a high matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio are present in tracheal aspirate fluids of infants who develop chronic lung disease

Pediatrics

Volumn 113, Issue 6 I, 2004, Pages 1709-1714

  Ekekezie, Ikechukwu I ^a,d   Thibeault, Donald W ^a   Simon, Stephen D ^b   Norberg, Michael ^a   Merrill, Jeffrey D ^c   Ballard, Roberta A ^c   Ballard, Philip L ^c   Truog, William E ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b Office of Medical Research   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Chronic lung disease; MMPs; TIMPs

Indexed keywords

GELATINASE A; GELATINASE B; GELATINASE INHIBITOR; IMMUNOGLOBULIN A; MATRIX METALLOPROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; ZINC DERIVATIVE;

ARTICLE; BIRTH WEIGHT; CHRONIC LUNG DISEASE; CLINICAL ARTICLE; DISEASE ASSOCIATION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FEMALE; GENDER; GESTATIONAL AGE; HUMAN; INFANT; INFLAMMATION; LOGISTIC REGRESSION ANALYSIS; LUNG VENTILATION; MALE; PATHOGENESIS; PREDICTION; PREMATURITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; STATISTICAL SIGNIFICANCE; TRACHEA MUCUS; TREATMENT OUTCOME;

BRONCHOPULMONARY DYSPLASIA; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; LOGISTIC MODELS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; RESPIRATION, ARTIFICIAL; RISK FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRACHEA;

EID: 2542544379     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.113.6.1709     Document Type: Article

References (27)

1. Parker RA, Lindstrom DP, Cotton RB. Improved survival accounts for most, but not all, of the increase in bronchopulmonary dysplasia. Pediatrics. 1992;90:663-668
2. Abman SH, Groothius JR. Pathophysiology and treatment of bronchopulmonary dysplasia: current issues. Pediatr Clin North Am. 1998;41:277-315
3. Ogden BE, Murphy SA, Saunders GC, et al. Neonatal lung neutrophils and elastase/proteinase inhibitor imbalance. Am Rev Respir Dis. 1984;130:817-821
4. Merritt TA, Cochrane DG, Holcomb K, et al. Elastase and a 1-proteinase inhibitor activity in tracheal aspirates during respiratory distress syndrome. Role of inflammation in the pathogenesis of bronchopulmonary dysplasia. J Clin Invest. 1983;72:656-666
5. Watterberg KL, Carmichael DF, Gerdes JS, et al. Secretory leukocyte protease inhibitor and lung inflammation in developing bronchopulmonary dysplasia. J Pediatr. 1994;125:264-269
6. Stiskal JA, Dunn MS, Shennan AT. Alpha-1-proteinase inhibitor therapy for the prevention of chronic lung disease of prematurity: a randomized, controlled trial. Pediatrics. 1998;101:89-94
7. Nagase H. Matrix metalloproteinases. In: Hooper NM, ed. Zinc Metalloproteases in Health and Disease. London, United Kingdom: Taylor & Francis Ltd; 1996:153-204
8. Infeld MD. Cell-matrix interactions in gland development in the lung. Exp Lung Res. 1997;23:161-169
9. Buisson AC, Zahm JM, Polette M, et al. Gelatinase B is involved in the in vitro wound repair of human respiratory epithelium. J Cell Physiol. 1996;166:413-426
10. Mautino G, Oliver N, Chanez P, et al. Increased release of matrix metalloproteinase-9 in bronchoalveolar lavage fluid and by alveolar macrophages of asthmatics. Am J Respir Cell Mol Biol. 1997;17:583-592
11. Ricou B, Nicod L, Lacraz S, et al. Matrix metalloproteinases and TIMP in acute respiratory distress syndrome. Am J Respir Crit Care Med. 1996;154(suppl):346-352
12. Lemjabbar H, Gosset P, Lechapt-Zalcman E, et al. Overexpression of alveolar macrophage gelatinase B (MMP-9) in patients with idiopathic pulmonary fibrosis: effects of steroid and immunosuppressive treatment. Am J Respir Cell Mol Biol. 1999;20:903-913
13. Finlay GA, Russell KH, McMahon KJ, et al. Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax. 1997;52:502-506
14. Clark PL, Ekekezie II, Kaftan HA, et al. Safety and efficacy of nitric oxide in chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 2002;86:F41-F45
15. Goil S, Barnes C, Thibeault D, et al. A simplified method of purification of colostrum to obtain secretory components of IgA, using secretory component as a reference protein in tracking aspirate blood. J Chromatogr B. 1998;704:203-211
16. Cederqvist K, Sorsa T, Tervanartiala T, et al. Matrix metalloproteinases-2, -8, and -9 and TIMP-2 in tracheal aspirates from preterm infants with respiratory distress. Pediatrics. 2001;108:686-692
17. Sweet DG, Pizzoti J, Wilbourn M, et al. Matrix metalloproteinase-9 (MMP-9) in the airways of infants at risk of developing chronic lung disease (CLD). Eur Respir J 1999;14(suppl 30):248s
18. Ekekezie II, Thibeault DW, Truog WE, et al. Characterization of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in the tracheal aspirate (TA) of ventilated infants. Pediatr Res. 2001;49:386A
19. Danan C, Jarreau PH, Franco ML, et al. Gelatinase activities in the airways of premature infants and development of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol. 2002;283:L1086-L1093
20. Schock BC, Sweet DG, Ennis M, et al. Oxidative stress and increased type-IV collagenase levels in bronchoalveolar lavage fluid from newborn babies. Pediatr Res. 2001;50:29-33
21. Alnahhas MH, Karathanasis P, Kriss VM, et al. Elevated laminin concentrations in lung secretions of preterm infants supported by mechanical ventilation are correlated with radiographic abnormalities. J Pediatr. 1997;131:555-560
22. Watts CL, Fanaroff AA, Bruce MC. Elevation of fibronectin levels in lung secretions of infants with respiratory distress syndrome and development of bronchopulmonary dysplasia. J Pediatr. 1992;120:614-620
23. Bruce MC, Wedig KE, Jentoft N, et al. Altered urinary excretion of elastin cross-links in premature infants who develop bronchopulmonary dysplasia. Am Rev Respir Dis. 1985;131:568-572
24. Gipson TS, Bless NM, Shanley TP, et al. Regulatory effects of endogenous protease inhibitors in acute lung inflammatory injury. J Immunol. 1999;162:3653-3662
25. Kumagai K, Olmo I, Okada S, et al. Inhibition of matrix metalloproteinases prevents allergen-induced airway inflammation in a murine model of asthma. J Immunol. 1999;162:4212-4219
26. Pilette C, Ouadrhiri Y, Dimanche F, et al. Secretory component is cleaved by neutrophil serine proteinases but its epithelial production is increased by neutrophils through NF-kappa B- and p38 mitogen-activated protein kinase-dependent mechanisms. Am J Respir Cell Mol Biol. 2003;28:485-498
27. Watts CL, Bruce MC. Comparison of secretory component for IgA with albumin as reference points in tracheal aspirate from preterm infants. J Pediatr. 1995;127:113-122